14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
Founder & Director, LPBI Group
Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
http://www.usaindiachamber.org
2021 summit- June 22. Marriott Cambridge, Massachusetts, USA
LPBI’s 2020 VISION
@pharma_BI
@AVIVA1950
#USAIC20
USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.
14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition |
14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,8 AM EST to 3-30 PM EST – Virtual Edition |
Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Timings are Eastern Standard Time (EST)
Time | Topic |
8 AM – 8-10 AM | Welcome address: Karun Rishi, President, USAIC
Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals
|
8-10 AM – 8-50 AM | Panel Discussion- COVID-19: Where are we now? Where are we going?
Panelists:
Moderator: |
8-50 AM – 8-55 AM | Break + Polling |
8-55 AM – 9-10 AM | India Regulatory update
Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India
Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization
Moderator:
|
9-10 AM – 9-15 AM | Break + Polling |
9-15 AM – 9-55 AM | Fireside Chat
Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit”
Moderator:
|
9-55 AM – 10 AM | Break + Polling |
10 AM – 10-40 AM | India Innovation Landscape
Panelists:
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group
Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India Resources are necessary 30% from Industry vs Government and Academe with great students and labs Indian context – Personalized Medicine – Telemedicine and IT infrastructure allowing innovation in a 1Billion Population- sheer volume of quality professional Dr. Naresh Trehan, Chairman, Medanta – the Medicity
Moderator:
|
10-40 AM – 10-45 AM | Break + Polling |
10-45 AM – 11-25 AM | Panel Discussion- Oncology: Changing landscape- COVID learnings and the promise of new technologies
Panelists:
Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute
Dr. Philip Larsen, Global Head of Research, Bayer AG
Rehan Verjee, President, EMD Serono
Dr. Tony Ho, Head of Research and Development, CRISPR Therapeutics
Moderator:
|
11-25 AM – 11-30 AM | Break + Polling |
11-30 AM – 12-10 PM | Panel Discussion- Industry & Investment Outlook
Panelists:
Daphne Zohar, Founder & CEO, PureTech Health
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University
Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator: President of Research & Development, Takeda Pharmaceuticals
Moderator Presenter: Dr. Michael Rosenblatt, CEO |
12-10 PM – 12-20 PM | Break + Polling |
12-20 PM – 1 PM | Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved
ROI is not there, regulatory requirements reduced, Registry Panelists:
Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda
Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals
Dr. John Orloff, Head of Research & Development, Alexion
Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation
Moderator:
|
1 PM – 1-05 PM | Break + Polling |
1-05 PM – 1-50 PM | Fireside Chat
Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals
Moderator:
|
1-50 PM – 1-55 PM | Break + Polling |
1-55 PM – 2-35 PM | Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World
Panelists:
Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co.
Dr. Maya Said, Chief Executive Officer, Outcomes4Me
https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice
Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson
Nina Kjellson, General Partner, Canaan
Moderator:
|
2-35 PM – 2-40 PM | Break + Polling |
2-40 PM – 3-20 PM | Panel Discussion- R&D Strategies and Trends: Innovation – The Big I
Panelists:
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline
Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson
Moderator: Moderator: Martin Mackay, Co-Founder, RallyBio
|
3-20 PM – 3-30 PM | Closing Remarks
|
Poll Questions for September 4
Polling Time (EST) | Polling Topic |
8-50 AM | COVID-19 PanelQuestion 1: What do you foresee as the most likely outcome of the race to develop a vaccine?
Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy?
|
9-10 AM | India Regulatory UpdateHow will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there:
|
9-55 AM | Fireside Chat: Ken Frazier
The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see?
|
10-40 AM | India Innovation LandscapeWhat is the most important step India could take to become a global leader in life sciences innovation?”
|
11-25 AM | Oncology PanelQuestion 1:
Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics
Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years?
|
12-10 PM | Industry & Investment Outlook PanelMore and more funding has been going into preclinical companies — do you expect this trend to continue?
R&D Strategies and Trends Panel COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic?
|
1 PM | Rare Diseases PanelWhat is the biggest barrier to access to Orphan drugs in low-income countries?
|
1-50 PM | Fireside Chat: Roy VagelosQuestion 1:
Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic
Question 2: COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic?
|
2-35 PM | Digital & Data Sciences PanelWhere has COVID-19 had the biggest impact on your adoption and use of digital health technologies?
|
@@@@
In these unprecedented times due to COVID-19, USAIC is offering Free Registration for its annual summit. |
Click for free registration |
AGENDA & SPEAKERS
Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: “From N of One to N of a Billion”
- Moderated Fireside Chat- Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. and Stelios Papadopoulos, Chairman of the Board, Biogen
- Moderated Fireside Chat- Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals and Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
- Moderated Fireside Chat- K. VijayRaghavan, Principal Scientific Advisor, Government of India and Amitabh Kant, CEO, National Institution for Transforming India (NITI)
Panel Discussions:
- Covid-19: Where are we now? Where are we going?
- Oncology: A never ending tunnel?
- Rare Diseases: Breaking Barriers for a Healthy Brain
- Digital & Data Sciences: Leveraging data and digital to achieve healthcare solutions
- Industry & Investment Outlook
- R&D Strategies and Trends: Innovation – The Big I
Program and speakers subject to change*
SOURCE:
Leave a Reply